Different Medications to Induce Labor
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Feb 6, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different medications, misoprostol and pitocin, to see which one is better at helping women with obesity (defined as having a body mass index, or BMI, of 30 or higher) to start labor when they are pregnant. The trial involves using a special device called a foley catheter, which is inserted to help the cervix get ready for labor. If you are a pregnant woman with a BMI of 30 or more and are planning to go to labor and delivery for induction, you may be eligible to participate in this study.
If you join the study, you can expect to be randomly assigned to receive either misoprostol or pitocin, along with the foley catheter. This means you might receive one medication or the other, but you won’t get to choose which one. The goal is to find out which medication works better for women with a higher BMI. This trial is currently looking for participants, so if you meet the eligibility criteria, you could help us learn more about effective labor induction methods for women in similar situations.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - Pregnant patient presenting to labor \& delivery for induction of labor with a BMI \> = 30
- Exclusion Criteria:
- • - Pregnant patient presenting to labor \& delivery for induction of labor with BMI \< 30
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Bronx, New York, United States
Patients applied
Trial Officials
Nicola F Tavella, MPH
Study Director
Icahn School of Medicine at Mount Sinai
Angela Bianco, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported